A recent Northwestern Medicine study has discovered a previously unknown molecular mechanism that supports antitumor responses and cell survival in cytotoxic immune cells, according to findings published in the Journal of ...
Apr 9, 2024
0
1
Researchers in the lab of chemist Han Xiao at Rice University have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.
Jan 24, 2024
0
50
Tumor-infiltrating lymphocytes (TILs) play a key role in the antitumor immune response and various types of immunotherapies. Recently, studies have shown that CD4+ T cells and CD8+ T cells are equally important for an efficient ...
May 12, 2022
0
4
A recent study published in Oncogene and led by Dr. Sun Yu's group at Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences revealed the roles and functional mechanisms of senescence-associated ...
Oct 25, 2022
0
7
Cancerous tumors thrive on blood, extending their roots deep into the fabric of the tissue of their host. They alter the genetics of surrounding cells and evolve to avoid the protective attacks of immune cells. Now, Penn ...
May 3, 2021
0
73
Triple-negative breast cancer (TNBC) tumors gain immunosuppression and chemoresistance through interactions between interleukin 34 and myeloid-derived suppressor cells, researchers find.
Nov 1, 2022
0
10
Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have identified new findings about an immune cell - called a tumor-associated macrophage - that promotes cancer instead ...
Sep 21, 2017
0
2
A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment ...
Nov 9, 2023
0
28
Cancer researchers are setting their sights on a new kind of cancer treatment that targets the tumor's surrounding environment, called the tumor microenvironment, in contrast to targeting the tumor directly.
Sep 4, 2019
0
1
In a small, investigator-initiated Phase II study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated ...
Apr 5, 2024
0
0
